This announcement is a separate document:
长春高新：关于控股子公司Ⅱ型单纯疱疹病毒mRNA疫苗临床试验申请获得批准的公告
Changchun Hi-Tech: Announcement on approval of the holding subsidiary\'s application for clinical trials of the herpes simplex virus mRNA vaccine
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated